NEW RESEARCH—Rituximab-treated patients during various phases of the #COVID19 pandemic in the UK. Severe COVID19 outcomes were similar to other severe infections, and numbers of comorbidities and hypogammaglobulinaemia were predictors of severe outcomes thelancet.com/journals/lanrh…
2
16
50
14K
3
Download Image
Navigating use of #rituximab during the #COVID19 pandemic Linked Comment by @elahee_mehreen & @SattuiSEMD thelancet.com/journals/lanrh…
@TheLancetRheum Interesting study; only 5% had hypogammaglobulinaemia (<6); this finding might be confirmed in a cohort of AAV patients, as 25-30% will have hypogamma following rituximab